Literature DB >> 2289996

Impact of dosage schedule of antibiotics on the treatment of serious infections.

I A Bakker-Woudenberg1, R Roosendaal.   

Abstract

Experimental studies suggest that the importance of the antibiotic dosage schedule for therapeutic efficacy in severe infection and when host defences are impaired is related to the class of antibiotic. The efficacy of beta-lactams is mainly dependent on the maintenance of adequate antibiotic concentrations in plasma during the entire treatment interval, and not on high peak concentrations. The efficacy of aminoglycosides is related to the total dose administered, i.e., the area under the concentration-time curve, irrespective of the frequency of administration. This difference in efficacy between beta-lactams and aminoglycosides in relation to the dosage schedule correlate well with differences between both classes of antibiotics in kinetics of antibacterial activity in vitro and in vivo. Another factor relevant in this respect is the post-antibiotic effect (PAE) which means the suppression of bacterial regrowth at the end of the period of exposure to antibiotic.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2289996     DOI: 10.1007/bf01709706

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  37 in total

1.  Continuous infusion of ceftazidime in cystic fibrosis.

Authors:  T J David; J Devlin
Journal:  Lancet       Date:  1989-06-24       Impact factor: 79.321

2.  The postantibiotic effect.

Authors:  W A Craig; B Vogelman
Journal:  Ann Intern Med       Date:  1987-06       Impact factor: 25.391

3.  Cure of Pseudomonas aeruginosa infection in neutropenic patients by continuous infusion of ceftazidime.

Authors:  S Daenen; H de Vries-Hospers
Journal:  Lancet       Date:  1988-04-23       Impact factor: 79.321

4.  Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance.

Authors:  J Blaser; B B Stone; M C Groner; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

5.  Postantibiotic suppression of bacterial growth.

Authors:  R W Bundtzen; A U Gerber; D L Cohn; W A Craig
Journal:  Rev Infect Dis       Date:  1981 Jan-Feb

6.  Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats.

Authors:  R Roosendaal; I A Bakker-Woudenberg; M van den Berghe-van Raffe; J C Vink-van den Berg; B M Michel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

7.  Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice: comparison of murine and human pharmacokinetics.

Authors:  A U Gerber; H P Brugger; C Feller; T Stritzko; B Stalder
Journal:  J Infect Dis       Date:  1986-01       Impact factor: 5.226

8.  Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice.

Authors:  A U Gerber; W A Craig; H P Brugger; C Feller; A P Vastola; J Brandel
Journal:  J Infect Dis       Date:  1983-05       Impact factor: 5.226

9.  Kinetics of antimicrobial activity.

Authors:  B Vogelman; W A Craig
Journal:  J Pediatr       Date:  1986-05       Impact factor: 4.406

10.  Dosage schedules of antimicrobial agents: a historical review.

Authors:  C M Kunin
Journal:  Rev Infect Dis       Date:  1981 Jan-Feb
View more
  7 in total

1.  Therapeutic drug monitoring of antimicrobials.

Authors:  Jason A Roberts; Ross Norris; David L Paterson; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

2.  Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.

Authors:  Phillip J Bergen; Jürgen B Bulitta; Carl M J Kirkpatrick; Kate E Rogers; Megan J McGregor; Steven C Wallis; David L Paterson; Roger L Nation; Jeffrey Lipman; Jason A Roberts; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 3.  Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.

Authors:  Jason A Roberts; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group.

Authors:  J Lipman; J Scribante; A G Gous; H Hon; S Tshukutsoane
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

5.  Altered pharmacokinetics of ceftazidime in critically ill patients.

Authors:  C M Gómez; J J Cordingly; M G Palazzo
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

6.  Development of a Novel Pharmaceutical Formula of Nanoparticle Lipid Carriers of Gentamicin/α-Tocopherol and In Vivo Assessment of the Antioxidant Protective Effect of α-Tocopherol in Gentamicin-Induced Nephrotoxicity.

Authors:  Mahmoud A Elfaky; Abrar K Thabit; Alaa Sirwi; Usama A Fahmy; Raghdah M Bahabri; Eman A Al-Awad; Lamis F Basaeed
Journal:  Antibiotics (Basel)       Date:  2019-11-25

7.  Aminoglycosides use has a risk of acute kidney injury in patients without prior chronic kidney disease.

Authors:  Yung-Ho Hsu; Tzu-Hao Chang; Chu-Lin Chou; Nai-Chen Chuang; Hui-Wen Chiu; Chia-Te Liao
Journal:  Sci Rep       Date:  2022-10-14       Impact factor: 4.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.